Quick Takes of the Week to July 24
WasteCo said Roger Gower stepped down as director and chair, with Sean Joyce replacing him. WasteCo reported FY26 revenue up 24% to $70.2m but a net loss of $12.35m. Tower appointed Len Elikhis as permanent CFO. Stats NZ put June-quarter inflation at 4.1%. AFT Pharma received tentative FDA approval for Scomara. SkyCity outlined a non-binding Grand Hotel sale deal.
How this was made
The 30-second read
Why it matters
The highest trading relevance comes from regulatory progress (AFT) and a conditional monetization plan (SkyCity). Other items are mostly governance/execution signals with limited immediate fundamentals. A macro CPI print driven by fuel adds context for rate and cost-of-living expectations.
Market read
Traders should focus on the FDA tentative approval pathway for AFT and the conditional, late-2026 cash proceeds for SkyCity. The rest are mostly medium-term execution and governance signals.
What to watch
For AFT, “tentative approval” and orphan exclusivity constraints may delay or limit revenue impact; for SkyCity, the non-binding nature and late 2026 cash timing reduce near-term debt relief certainty.
Background
This is a weekly “quick takes” roundup covering multiple NZX-listed corporate updates, including board/executive changes, a tentative FDA decision for an NZ biotech, and a conditional asset sale aimed at debt reduction.
Ticker impact
WasteCo’s interim CEO and chair Roger Gower stepped down, with a new chair and ongoing turnaround efforts amid a reported net loss.
Likely modest, sentiment-driven reaction unless investors view the change as improving turnaround odds.
The article discloses a director/board change and mentions poor performance and a net loss, but does not provide new targets, financing terms, or operational milestones.
Mercury invested $53m to buy a 12.7% stake in data centre d... (article truncates before naming the target).
Potential positive read-through for data-centre exposure, but uncertainty remains due to incomplete deal details in the provided text.
The article discloses the investment size and stake percentage, but truncation prevents confirming the asset, valuation terms, and strategic rationale.
Market effects
US FDA tentative approval supports sentiment for NZ biotech commercialization pathways; insurance and telco executive changes may influence perceived execution quality in regulated sectors.
New Zealand listed-company governance and capital allocation updates may affect NZX sentiment, especially around deleveraging narratives (SkyCity) and inflation backdrop (fuel-driven CPI).
Revolut’s Australia banking licence is a cross-border fintech regulatory milestone, relevant to global neobanking competitive dynamics.
Counterpoint
Several items are governance or leadership changes without immediate financial impact; the most tradable catalysts (AFT FDA and SkyCity sale) still carry execution and timing risk.
Key entities
- companyWasteCo
NZX-listed waste solutions and industrial services provider, with chair/CEO director changes amid weak performance.
- companyTower Insurance
NZX-listed insurer appointing a permanent CFO with insurance finance and transformation experience.
- companyAFT Pharmaceuticals
NZX-listed biotech receiving tentative FDA approval for Scomara cream in a rare disease indication.
- companySkyCity
Casino operator announcing a conditional sale of its Auckland Grand Hotel to reduce debt.
- companyMove Logistics Group
Logistics firm appointing an independent director to chair its audit and risk committee.
